Lezárult
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults with Advanced Colorectal Cancer.
2025-523984-39-00· 2. fázis· Gilead Sciences Inc.· Forrás
Lezárult
A Phase 1 Study of ATV-1601, in Patients with Advanced Cancer that have AKT1 E17K Mutations
2025-521480-12-00· 1. fázis· Atavistik Bio Inc.· Forrás
Lezárult
A trial to learn how safe saruparib is and how well it works in people with advanced ovarian cancer
2024-519044-32-00· 1/2. fázis· AstraZeneca AB· Forrás
Lezárult
A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on their Biomarker Status
2024-511239-91-00· 2. fázis· F. Hoffmann-La Roche AG· Forrás
Lezárult
An Open-Label, Multicenter, Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1604 in Adults with Advanced Melanoma
2024-511949-19-00· 1. fázis· Sairopa B.V.· Forrás
Lezárult
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
NCT06433219· 2. fázis· EMD Serono Research & Development Institute, Inc.· Forrás
Lezárult
Effect of Copper CU64 PSMA I&T scanning to detect potential disease spread to lymph nodes in men with newly diagnosed Prostate Cancer
2024-512754-16-01· 3. fázis· Curium US LLC· Forrás
Fut, nem toboroz
A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC
2023-504753-12-00· 3. fázis· Glaxosmithkline Research & Development Limited· Forrás
Fut, nem toboroz
A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients
NCT06540391· 1. fázis· Microbiotica Ltd· Forrás
Fut, nem toboroz
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
NCT06328738· 1. fázis· Enliven Therapeutics· Forrás
Lezárult
A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer
NCT06395753· 2. fázis· Debiopharm International SA· Forrás
Fut, nem toboroz
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
NCT05853575· 2. fázis· Mirati Therapeutics Inc.· Forrás
Leállították
Study of ALE.C04 in Patients With Head and Neck Cancer
NCT06054477· 1/2. fázis· Alentis Therapeutics AG· Forrás
Lezárult
A clinical study of bemcentinib with standard of care chemoimmunotherapy in untreated advanced/metastatic non-small cell lung cancer patients with a mutation in the STK11 gene
NCT05469178· 1/2. fázis· Bergenbio ASA· Forrás
Lezárult
A first-in-human dose escalation and expansion study with the SIRPα-directed monoclonal antibody BYON4228 alone and in combination with rituximab to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy in patients with relapsed/refractory CD20 positive B-cell Non-Hodgkin’s Lymphoma (NHL)
2024-512390-27-00· 1. fázis· Byondis B.V.· Forrás
Lezárult
Phase 2 Study of Encorafenib and Binimetinib Plus Pembrolizumab in Participants With BRAF V600E/K Mutation-Positive Melanoma Who Progressed During or After Prior Treatment with Anti−PD-1 Therapy
2023-509471-17-00· 2. fázis· Pfizer Inc.· Forrás
Fut, nem toboroz
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
NCT05908734· 1/2. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
A Phase 2 Study of MORAb-202 in Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
2023-504111-33-00· 2. fázis· Bristol Myers Squibb International Corporation· Forrás
Lezárult
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors
NCT05668585· 1. fázis· C4 Therapeutics, Inc.· Forrás
Lezárult
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRα) Antibody Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)
NCT05200364· 1. fázis· Sutro Biopharma Inc.· Forrás
Lezárult
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
NCT05568095· 3. fázis· Arcus Biosciences, Inc.· Forrás
Lezárult
A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma
NCT05309421· 2. fázis· Evaxion Biotech A/S· Forrás
Toboroz
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT05254171· 2/3. fázis· Panbela Therapeutics, Inc.· Forrás
Fut, nem toboroz
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT05388669· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
NCT05364073· 1. fázis· ArriVent BioPharma, Inc.· Forrás
Fut, nem toboroz
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
NCT05257408· 3. fázis· Corcept Therapeutics· Forrás
Fut, nem toboroz
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
NCT05307705· 1. fázis· Eli Lilly and Company· Forrás
Lezárult
Neoadjuvant Nivolumab and chemotherapy in stage I-II triple negative breast cancer.
2024-512625-86-00· 2. fázis· ANZ Breast Cancer Trials Group Limited· Forrás
Fut, nem toboroz
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Inoperable or Metastatic Hormone Receptor-positive, HER2-negative Breast Cancer
NCT05104866· 3. fázis· AstraZeneca AB· Forrás
Fut, nem toboroz
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
NCT05091567· 3. fázis· Hoffmann-La Roche· Forrás
Lezárult
An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)
2024-512717-41-00· 2. fázis· Viracta Therapeutics Inc.· Forrás
Lezárult
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer
NCT05117242· 2. fázis· Genmab A/S· Forrás
Lezárult
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
NCT04987203· 3. fázis· AVEO Pharmaceuticals, Inc.· Forrás
Lezárult
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
NCT04925284· 1. fázis· Exelixis· Forrás
Lezárult
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
NCT04660812· 1/2. fázis· Arcus Biosciences, Inc.· Forrás
Fut, nem toboroz
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
NCT04657991· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
NCT04625270· 2. fázis· Verastem, Inc.· Forrás
Fut, nem toboroz
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
NCT04656652· 3. fázis· Daiichi Sankyo· Forrás
Lezárult
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)
NCT03906071· 3. fázis· Mirati Therapeutics Inc.· Forrás
Fut, nem toboroz
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
NCT04658862· 3. fázis· Janssen Research & Development, LLC· Forrás
Még nem toboroz
Impact on Disease Relapse of HPV Vaccination in Women Treated With LEEP for Cervical Intraepithelial Neoplasia. HOPE9
NCT03848039· 3. fázis· Alessandro Ghelardi· Forrás
Fut, nem toboroz
A study of tucatinib vs. placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with advanced or metastatic HER2+ breast cancer
NCT03975647· 3. fázis· Seagen Inc.· Forrás
Lezárult
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
NCT04221945· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A trial to learn how camizestrant (AZD9833) works compared to fulvestrant and how safe it is in women with advanced breast cancer who have gone through menopause.
NCT04214288· 2. fázis· AstraZeneca AB· Forrás
Lezárult
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
NCT03940703· 2. fázis· EMD Serono Research & Development Institute, Inc.· Forrás
Lezárult
GEN1046 Safety Trial in Patients With Malignant Solid Tumors
NCT03917381· 1/2. fázis· Genmab A/S· Forrás
Fut, nem toboroz
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
NCT03816163· 2. fázis· Astellas Pharma Global Development, Inc.· Forrás
Lezárult
Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
NCT03519412· 2. fázis· IFOM ETS - The AIRC Institute of Molecular Oncology· Forrás
Fut, nem toboroz
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
NCT03737643· 3. fázis· AstraZeneca· Forrás
Lezárult
A study to find out if an investigational product, called LN-145 (also called tumor infiltrating lymphocytes) is an effective and safe treatment in patients with recurrent, metastatic or persistent cervical carcinoma
NCT03108495· 2. fázis· Iovance Biotherapeutics Inc.· Forrás
Showing 50 of 55.